Get the Stockscreener App
10.66
0.37%
-0.04
After Hours:
10.66
Telix Pharmaceuticals Ltd Adr stock is traded at $10.66, with a volume of 321.75K.
It is down -0.37% in the last 24 hours and up +35.80% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$10.70
Open:
$10.65
24h Volume:
321.75K
Relative Volume:
1.28
Market Cap:
$3.61B
Revenue:
$804.63M
Net Income/Loss:
$-7.13M
P/E Ratio:
-505.21
EPS:
-0.0211
Net Cash Flow:
$-73.42M
1W Performance:
+9.00%
1M Performance:
+35.80%
6M Performance:
-3.18%
1Y Performance:
-36.62%
1-Day Range:
$10.41
$10.69
1-Week Range:
$9.66
$11.48
52-Week Range:
$6.28
$20.00
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
10.66 | 3.62B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga
Telix and Regeneron Announce Strategic Radiopharma Collaboration - Sahm
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Strengthens Board with Additional Director Appointments - Sahm
Telix Appoints David Gill as Non-Executive Director - Sahm
[Form 4] Telix Pharmaceuticals Ltd Insider Trading Activity - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3.63M indirect shares - Stock Titan
Telix (TLX) COO reports ordinary shares, ADRs and option-like awards - Stock Titan
Telix Pharmaceuticals (TLX) files 20-F/A to correct exhibit links - Stock Titan
Telix Pharmaceuticals (TLX) director reports 595,000 shares held via Forellan - Stock Titan
Telix (TLX) CEO details ADRs, options and large indirect stake - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3,719 Ordinary Shares - Stock Titan
Telix Pharmaceuticals Limited (TLX) Stock Price, News, Quote & History - Yahoo Finance
Telix (NASDAQ: TLX) resubmits FDA NDA for Pixclara brain cancer imaging agent - Stock Titan
Latest TLX NewsTelix to Showcase Urology Pipeline at Upcomi... - Stock Titan
Stock of the day: Telix Pharmaceuticals - ig.com
Telix Signals Upcoming Escrow Share Release - Colitco
How new prostate scans could change care: Telix hosts doctor Q&A - Stock Titan
Global prostate scan registry taps AI to predict survival - Stock Titan
Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why - Finviz
Telix leaders to speak at Oppenheimer and TD Cowen, sessions streamed live - Stock Titan
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Telix submits European marketing application for brain cancer imaging agent By Investing.com - Investing.com India
Telix Pharmaceuticals stock rises after European regulatory submission By Investing.com - Investing.com India
Sea Limited Sponsored ADR (SE) Rises Higher Than Market: Key Facts - Yahoo Finance
New Telix brain scan aims to distinguish tumor growth from treatment effects - Stock Titan
Are Investors Undervaluing Yankuang Energy Group Company Limited Sponsored ADR (YZCAY) Right Now? - Yahoo Finance
Here's Why PDD Holdings Inc. Sponsored ADR (PDD) Fell More Than Broader Market - Yahoo Finance
Sea Limited Sponsored ADR (SE) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Is ANZ Group Holdings LimitedSponsored ADR (ANZGY) Outperforming Other Finance Stocks This Year? - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Advances While Market Declines: Some Information for Investors - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Sea Limited Sponsored ADR (SE) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RBC Capital upgrades Telix Pharmaceuticals stock rating to Outperform - Investing.com
Telix begins phase 3 trial to reduce prostate cancer biopsies - Investing.com South Africa
Telix Pharmaceuticals Within The Evolving Precision Oncology Space - Kalkine Media
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Sahm
Here's What Analysts Think About Telix Pharmaceuticals (TLX) - Finviz
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact The Gross Law Firm about pending Class ActionTLX - Sahm
Telix Pharmaceuticals Ltd. Sued for Securities Law ViolationsContact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Barchart.com
Health conference talk to spotlight Telix therapeutic pipeline and products - Stock Titan
Sea Limited Sponsored ADR (SE) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
New Strong Buy Stocks for January 6th - Yahoo Finance
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):